Addison Advisors LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Addison Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJFree Report) by 7.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,409 shares of the company’s stock after purchasing an additional 590 shares during the quarter. Addison Advisors LLC’s holdings in Johnson & Johnson were worth $1,310,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Hibernia Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $27,000. FNY Investment Advisers LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $37,000. Tower View Wealth Management LLC raised its position in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC raised its position in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $48,000. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $157.98 on Thursday. The company’s 50 day moving average price is $158.20 and its 200 day moving average price is $159.04. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a market capitalization of $380.30 billion, a PE ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the firm posted $2.35 earnings per share. The firm’s revenue was down 9.7% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.01%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is 34.47%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on JNJ shares. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Barclays boosted their target price on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Get Our Latest Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.